Biote Corp. Form 8-K Summary
Business context and reporting period
Biote Corp. filed this Current Report on April 29, 2024, regarding a material settlement agreement executed on April 23, 2024, with stockholder Dr. Gary S. Donovitz. The filing does not report quarterly operating results; it addresses the resolution of previously disclosed litigation.
Material transaction and financial impact
- The Company agreed to repurchase all Class A common units of Biote Holdings, LLC, paired Class V common stock and Holdings Units, and Class A common stock beneficially owned by Donovitz for approximately $76.9 million in aggregate.
- Approximately $32.2 million was paid on April 26, 2024, for approximately 5.1 million Class A Shares and 3.1 million Paired Interests.
- Approximately $15.1 million is payable on the 12-month anniversary of the closing date for approximately 4.1 million Paired Interests.
- Approximately $19.1 million is payable on the 24-month anniversary for approximately 4.1 million Paired Interests.
- Approximately $10.5 million is payable on the 36-month anniversary for approximately 2.0 million Paired Interests.
- The filing provides no new revenue, profit, cash-flow, margin, debt, liquidity, or other operating metrics.
Changes versus the prior comparable disclosure
- The definitive Settlement Agreement superseded the binding settlement term sheet announced on February 13, 2024 and disclosed in the Company’s February 20, 2024 Form 8-K.
- The transaction formalized the previously disclosed settlement framework and established specific repurchase amounts and payment dates.
Settlement terms, outlook, and risks
- The parties agreed to mutual releases of claims arising from or related to the litigation.
- Donovitz’s founder advisory agreement with BioTE Medical, LLC terminated effective April 26, 2024.
- Donovitz agreed to two-year non-compete and non-solicitation restrictions and a customary voting agreement acceptable to the Company.
- The settlement creates approximately $44.7 million of additional scheduled payments after the initial closing payment, subject to the agreement’s terms.
- The filing does not explain the source of funds, accounting treatment, effect on liquidity, or potential impact on future financial results.
- The definitive agreement was not included in the filing; the Company stated that it will file a copy in its next Form 10-Q.
Key facts for investors to verify
- Verify the final Settlement Agreement and its representations, covenants, release provisions, and payment conditions when filed with the next Form 10-Q.
- Review the Company’s cash balances, financing arrangements, and liquidity disclosures to assess its ability to make the approximately $44.7 million of deferred payments.
- Confirm the accounting treatment and any liabilities, expenses, or changes in share count resulting from the repurchases.
- Assess whether the settlement affects ownership, voting control, governance, or the Company’s future relationship with Donovitz.